Form 13-F position report

HAVARD BIOSCIENCE INC

Reported by BlackRock Inc

HBIO CUSIP 416906105 Manager CIK 0001364742

Reported 1,209,119 shares, down 1,848,883 (60.5%) from the prior quarter.

Reported value -77.1%; share count -60.5% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 1,209,119 Quarter-end amount reported
Reported value $4,353,000 Fair value at quarter end
Consecutive quarters held 22 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-09-30 19107000
2021-12-31 21595000
2022-03-31 18990000
2022-06-30 4353000
2022-09-30 3052000
2022-12-31 2504292
2023-03-31 3799929
2023-06-30 14404394
2023-09-30 11793512
2023-12-31 15588905
2024-03-31 12014736
2024-06-30 8104403
2024-09-30 7844513
2024-12-31 6290778
2025-03-31 1596382
2025-06-30 494648
2025-09-30 272470
2025-12-31 416191
2026-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

19 quarters
Quarterly reported position history for HAVARD BIOSCIENCE INC held by BlackRock Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2026 Reduced 0 -622,296 (-100.0%) 0 $0 2026-05-13
Q4 2025 Added 622,296 +929 (0.1%) < 0.01% $416,191 2026-02-12
Q3 2025 Reduced 621,367 -493,208 (-44.3%) < 0.01% $272,470 2025-11-12
Q2 2025 Reduced 1,114,575 -1,705,887 (-60.5%) < 0.01% $494,648 2025-08-12
Q1 2025 Reduced 2,820,462 -160,949 (-5.4%) < 0.01% $1,596,382 2025-05-02
Q4 2024 Added 2,981,411 +65,235 (2.2%) < 0.01% $6,290,778 2025-02-07
Q3 2024 New 2,916,176 +2,916,176 (0.0%) < 0.01% $7,844,513 2024-11-13
Q2 2024 Added 2,843,650 +9,986 (0.4%) < 0.01% $8,104,403 2024-08-13
Q1 2024 Reduced 2,833,664 -80,150 (-2.8%) < 0.01% $12,014,736 2024-05-10
Q4 2023 Added 2,913,814 +171,137 (6.2%) < 0.01% $15,588,905 2024-02-13
Q3 2023 Added 2,742,677 +118,926 (4.5%) < 0.01% $11,793,512 2023-11-13
Q2 2023 Added 2,623,751 +1,719,006 (190.0%) < 0.01% $14,404,394 2023-08-11
Q1 2023 Added 904,745 +669 (0.1%) < 0.01% $3,799,929 2023-05-12
Q4 2022 Reduced 904,076 -289,022 (-24.2%) < 0.01% $2,504,292 2023-02-13
Q3 2022 Reduced 1,193,098 -16,021 (-1.3%) < 0.01% $3,052,000 2022-11-14
Q2 2022 Reduced 1,209,119 -1,848,883 (-60.5%) < 0.01% $4,353,000 2022-08-12
Q1 2022 Reduced 3,058,002 -5,188 (-0.2%) < 0.01% $18,990,000 2022-05-12
Q4 2021 Added 3,063,190 +325,723 (11.9%) < 0.01% $21,595,000 2022-02-10
Q3 2021 Added 2,737,467 +6,043 (0.2%) < 0.01% $19,107,000 2021-11-09
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

115 managers reported HAVARD BIOSCIENCE INC for Q2 2022.

Managers reporting HAVARD BIOSCIENCE INC in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Harvey Partners LLC Added 2,865,000 +639,000 2.27% $10,314,000 12 qtrs
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT INC Added 2,654,247 +188,837 0.67% $9,555,000 9 qtrs
Portolan Capital Management LLC Reduced 2,451,861 -74,928 0.89% $8,827,000 9 qtrs
DIMENSIONAL FUND ADVISORS LP Reduced 1,877,842 -208 < 0.01% $6,760,000 37 qtrs
ROYCE & ASSOCIATES LP Reduced 1,620,263 -65,700 0.06% $5,833,000 37 qtrs
B Riley Asset Management LLC Added 1,544,647 +646,211 2.66% $5,561,000 3 qtrs
VANGUARD GROUP INC Reduced 1,538,283 -386,234 < 0.01% $5,538,000 37 qtrs
Granahan Investment Management LLC Added 1,532,693 +75,944 0.19% $5,518,000 37 qtrs
AMH Equity Ltd Added 1,250,000 +473,747 7.77% $4,500,000 3 qtrs
BlackRock Inc This report Reduced 1,209,119 -1,848,883 < 0.01% $4,353,000 22 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 12, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
1,176,670
Shared
0
None
32,449

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.